Nevirapine hemihydrate

Nevirapine Hemihydrate is a hemihydrated form of Nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination antiretroviral therapy for the treatment of HIV-1 infection. It works by binding directly to HIV-1 reverse transcriptase, causing a conformational change that inhibits the enzyme’s activity and prevents viral replication. Administered orally, it is typically started at a lower dose to reduce the risk of severe rash or hepatotoxicity, then increased to a maintenance dose. Though effective in improving immune function by increasing CD4+ counts, it may cause side effects including rash, liver toxicity, and, rarely, life-threatening skin reactions. Nevirapine Hemihydrate is included in the WHO Essential Medicines List and is FDA-approved for clinical use. It is grouped under the following drug class(es): Reverse Transcriptase Inhibitors. Its therapeutic use is listed as antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Nevirapine hydrate, 2-cyclopropyl-7-methyl-2, 4, 9, 15-tetrazatricyclo[9.4.0.03, 8]pentadeca-1(11), 3, 5, 7, 12 and 14-hexaen-10-one;hydrate. Its PubChem CID is 9959243.